Inhibikase Therapeutics Inc (IKT) - Total Assets
Based on the latest financial reports, Inhibikase Therapeutics Inc (IKT) holds total assets worth $79.59 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Inhibikase Therapeutics Inc - Total Assets Trend (2016–2024)
This chart illustrates how Inhibikase Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. Also see how much is Inhibikase Therapeutics Inc worth for the company's overall valuation and market capitalisation.
Inhibikase Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Inhibikase Therapeutics Inc's total assets of $79.59 Million consist of 99.9% current assets and 0.2% non-current assets. Review debt load of Inhibikase Therapeutics Inc to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 57.3% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Inhibikase Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See IKT share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Inhibikase Therapeutics Inc's current assets represent 99.9% of total assets in 2024, an increase from 49.2% in 2016.
- Cash Position: Cash and equivalents constituted 57.3% of total assets in 2024, up from 7.4% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Inhibikase Therapeutics Inc Competitors by Total Assets
Key competitors of Inhibikase Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Inhibikase Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 11.73 | 0.85 | 3.13 |
| Quick Ratio | 11.73 | 0.85 | 3.13 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $71.84 Million | $-717.36K | $10.06 Million |
Inhibikase Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Inhibikase Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.84 |
| Latest Market Cap to Assets Ratio | 1.21 |
| Asset Growth Rate (YoY) | 579.7% |
| Total Assets | $98.60 Million |
| Market Capitalization | $119.23 Million USD |
Valuation Analysis
Above Book Valuation: The market values Inhibikase Therapeutics Inc's assets above their book value (1.21x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Inhibikase Therapeutics Inc's assets grew by 579.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Inhibikase Therapeutics Inc (2016–2024)
The table below shows the annual total assets of Inhibikase Therapeutics Inc from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $98.60 Million | +579.69% |
| 2023-12-31 | $14.51 Million | -41.83% |
| 2022-12-31 | $24.94 Million | -41.28% |
| 2021-12-31 | $42.47 Million | +187.30% |
| 2020-12-31 | $14.78 Million | +38543.56% |
| 2019-12-31 | $38.25K | -98.66% |
| 2018-12-31 | $2.85 Million | +898.17% |
| 2017-12-31 | $285.17K | +75.03% |
| 2016-12-31 | $162.93K | -- |
About Inhibikase Therapeutics Inc
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a p… Read more